<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081792</url>
  </required_header>
  <id_info>
    <org_study_id>DFI_Cohort</org_study_id>
    <nct_id>NCT04081792</nct_id>
  </id_info>
  <brief_title>Optimal Antibiotics for Operated Diabetic Foot Infections</brief_title>
  <official_title>Optimization of the Surgical and Medical Management of Diabetic Foot Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Balgrist University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Balgrist University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic foot problems, especially infections (DFI), require multiple resources including
      iterative surgeries and amputations, long-lasting antibiotic therapies, education,
      off-loading and eventually revascularization and appropriate foot-ware. Treatment is
      complicated, multidisciplinary, and marked with a high risk of recurrences.

      This is a retrospective and prospective cohort with side studies of pathologies and academic
      research questions that cannot be separated from each other.

      The investigators establish a retro-and prospective cohort of diabetic foot problems
      (ambulatory and hospitalized patients) and perform side studies to reduce the incidence of
      complications, and to reduce recurrences of DFI, cost and adverse events related to
      therapies.

      Cohort: Prospective and retrospective cohort of all diabetic foot problems with emphasis on
      surgical and infectious variables.

      Trial 1 (Randomized trial on residual infection after amputation):

      Determination of the level of amputation per MRI followed by a randomization concerning the
      duration of post-amputation systemic antibiotic therapy, if there is residual bone infection.

      Trial 2 (Randomized trial on infection without amputation):

      Determination of the duration of systemic antibiotic therapy in diabetic foot infections
      without Amputation of the infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial 1: At enrollment (Day 1), the investigator will prescribe empiric antibiotic treatment
      based on instructions provided in the protocol and determine the most appropriate route of
      administration (oral or IV) according to the patient's condition. Patients will be randomized
      in the ratio 1:1 between 1 versus 4 days for post-amputation soft tissue infections; and
      between 1 versus 3 weeks if there is microbiologically proven residual bone
      infection/contamination in the proximal stump samples of the residual bone.

      Trial 2: At enrollment (Day 1), the investigator will prescribe empiric antibiotic treatment
      based on instructions provided in the protocol and determine the most appropriate route of
      administration (oral or IV) according to the patient's condition. Patients will be randomized
      in the ratio 1:1 between 10 versus 20 days for post-debridement soft tissue infections; and
      between 3 versus 6 weeks for diabetic foot osteomyelitis post.-debridement (without
      amputation).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with a clinical and microbiological remission of treated infection at 2 months</measure>
    <time_frame>Through study completion, at 2 months</time_frame>
    <description>Remission is the absence of any anamnesis or clinics for persistent or recurrent infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anatomical Amputation Level Determination by MRI</measure>
    <time_frame>At study entry, Day O</time_frame>
    <description>Evaluation of the accuracy of the extension of infection. Surgical decision for amputation level per magnetic resonance imaging when compared to microbiology, histology and intraoperative assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of adverse events of antibiotic therapy</measure>
    <time_frame>Through study completion, at 2 months</time_frame>
    <description>Outcome of antibiotic-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of wound healing time</measure>
    <time_frame>Through study completion, at 2 months</time_frame>
    <description>Evolution of wound size under therapy and off-loading over time. Wound Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of Cost and resource reductions</measure>
    <time_frame>Through study completion, at 2 months</time_frame>
    <description>Overall hospitalization and treatment costs; in Swiss Francs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scales of Patient's satisfaction</measure>
    <time_frame>Through study completion, at 2 months</time_frame>
    <description>Questionnaires and Scores (e.g. AOFAS Score) ranging from 0 to 1. Alternatively, a home made Likert Scale ranging from 0 to 7 Points will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistical evaluation of risk factors for failure of remission</measure>
    <time_frame>2 years</time_frame>
    <description>Multivariate Cox Regression analyses</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Diabetic Foot Infection</condition>
  <condition>Surgical Wound</condition>
  <condition>Antibiotic Side Effect</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>1. Trial (Amputation) Soft tissue - short antibiotic arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group consists of 1 day of postoperative antibiotic therapy for eventual residual soft tissue infection after amputation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1. Trial (Amputation) Soft tissue - long antibiotic arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group consists of 4 days duration of postoperative antibiotic therapy for eventual residual soft tissue infection after amputation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1. Trial (Amputation) Bone - short antibiotic arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group consists of 1 week of postoperative antibiotic therapy for eventual residual bone infection / contamination in the proximal bone stump after amputation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1. Trial (Amputation) Bone - long antibiotic arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The intervention group consists of 3 weeks of postoperative antibiotic therapy for eventual residual bone infection / contamination in the proximal bone stump after amputation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.Trial (soft tissue infection) - short antibiotic arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group consists of 10 days of post-debridement antibiotic therapy for non-amputated diabetic foot soft tissue infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Trial (soft tissue infection) - long antibiotic arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group consists of 20 days of post-debridement antibiotic therapy for non-amputated diabetic foot soft tissue infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Trial (osteomyelitis) - short antibiotic arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group consists of 3 weeks of post-debridement antibiotic therapy for non-amputated diabetic foot osteomyelitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Trial (osteomyelitis) - long antibiotic arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group consists of 6 weeks of post-debridement antibiotic therapy for non-amputated diabetic foot osteomyelitis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Antibiotic therapy</intervention_name>
    <description>Postoperative randomizations regarding the duration of systemic antibiotics</description>
    <arm_group_label>1. Trial (Amputation) Bone - long antibiotic arm</arm_group_label>
    <arm_group_label>1. Trial (Amputation) Bone - short antibiotic arm</arm_group_label>
    <arm_group_label>1. Trial (Amputation) Soft tissue - long antibiotic arm</arm_group_label>
    <arm_group_label>1. Trial (Amputation) Soft tissue - short antibiotic arm</arm_group_label>
    <arm_group_label>2. Trial (osteomyelitis) - long antibiotic arm</arm_group_label>
    <arm_group_label>2. Trial (osteomyelitis) - short antibiotic arm</arm_group_label>
    <arm_group_label>2. Trial (soft tissue infection) - long antibiotic arm</arm_group_label>
    <arm_group_label>2.Trial (soft tissue infection) - short antibiotic arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Diabetic foot infections or ischemia/necrosis with surgical amputation/disarticulation
             level in vicinity of MRI signs of infection

          -  At least two months of follow-up from hospitalization

          -  Patient signing to participate, including acceptance of local wound care, -off-loading
             and arterial re-vascularization (if clinically indicated).

        Exclusion Criteria:

          -  At least 5 cm of distance between amputation level and infection.

          -  Any concomitant infection requiring more than 5 days of systemic antibiotic therapy

          -  Eventual osteosynthesis material not removed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilker Uçkay, PD MD</last_name>
    <role>Study Director</role>
    <affiliation>Balgrist University Hospital, Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilker Uckay, PD MD</last_name>
    <phone>+41443863705</phone>
    <email>ilker.uckay@balgrist.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felix Waibel, MD</last_name>
    <phone>+41443865759</phone>
    <email>felix.waibel@balgrist.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Balgrist University Hospital</name>
      <address>
        <city>Zürich</city>
        <state>Zurich</state>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilker Uçkay, PD, MD</last_name>
      <phone>+41 44 386 37 05</phone>
      <email>ilker.uckay@balgrist.ch</email>
    </contact>
    <contact_backup>
      <last_name>Felix Waibel, MD</last_name>
      <phone>+41 44 386 57 59</phone>
      <email>felix.waibel@balgrist.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Martin C Berli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Madlaina Schöni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Burkhard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Holy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabrina Catanzaro, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kati Sairanen, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanja Huber, Pharm D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Uckay I, Jornayvaz FR, Lebowitz D, Gastaldi G, Gariani K, Lipsky BA. An Overview on Diabetic Foot Infections, including Issues Related to Associated Pain, Hyperglycemia and Limb Ischemia. Curr Pharm Des. 2018;24(12):1243-1254. doi: 10.2174/1381612824666180302145754. Review.</citation>
    <PMID>29508677</PMID>
  </reference>
  <reference>
    <citation>Cöster MC, Rosengren BE, Bremander A, Brudin L, Karlsson MK. Comparison of the Self-reported Foot and Ankle Score (SEFAS) and the American Orthopedic Foot and Ankle Society Score (AOFAS). Foot Ankle Int. 2014 Oct;35(10):1031-6. doi: 10.1177/1071100714543647. Epub 2014 Jul 11.</citation>
    <PMID>25015390</PMID>
  </reference>
  <results_reference>
    <citation>Rossel A, Lebowitz D, Gariani K, Abbas M, Kressmann B, Assal M, Tscholl P, Stafylakis D, Uçkay I. Stopping antibiotics after surgical amputation in diabetic foot and ankle infections-A daily practice cohort. Endocrinol Diabetes Metab. 2019 Feb 6;2(2):e00059. doi: 10.1002/edm2.59. eCollection 2019 Apr.</citation>
    <PMID>31008367</PMID>
  </results_reference>
  <results_reference>
    <citation>Uçkay I, Berli M, Sendi P, Lipsky BA. Principles and practice of antibiotic stewardship in the management of diabetic foot infections. Curr Opin Infect Dis. 2019 Apr;32(2):95-101. doi: 10.1097/QCO.0000000000000530.</citation>
    <PMID>30664029</PMID>
  </results_reference>
  <results_reference>
    <citation>Gariani K, Lebowitz D, von Dach E, Kressmann B, Lipsky BA, Uçkay I. Remission in diabetic foot infections: Duration of antibiotic therapy and other possible associated factors. Diabetes Obes Metab. 2019 Feb;21(2):244-251. doi: 10.1111/dom.13507. Epub 2018 Sep 21.</citation>
    <PMID>30129109</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetic foot; osteomyelitis; amputation; antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Focal Infection</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>not yet determined in detail</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>In 2022</ipd_time_frame>
    <ipd_access_criteria>Upon reasonable request upon the contact authors</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

